BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 10452322)

  • 21. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma.
    Kwekkeboom DJ; Bakker WH; Kooij PP; Erion J; Srinivasan A; de Jong M; Reubi JC; Krenning EP
    Eur J Nucl Med; 2000 Sep; 27(9):1312-7. PubMed ID: 11007512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiolabeled gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting.
    Kaloudi A; Nock BA; Krenning EP; Maina T; De Jong M
    Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):287-302. PubMed ID: 26158215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
    Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
    Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide.
    Sosabowski JK; Matzow T; Foster JM; Finucane C; Ellison D; Watson SA; Mather SJ
    J Nucl Med; 2009 Dec; 50(12):2082-9. PubMed ID: 19910426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
    Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
    Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiolabeling approaches for cholecystokinin B receptor imaging.
    Aloj L; Panico MR; Caracó C; Zannetti A; Del Vecchio S; Di Nuzzo C; Arra C; Morelli G; Tesauro D; De Luca S; Pedone C; Salvatore M
    Biopolymers; 2002; 66(6):370-80. PubMed ID: 12658724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison.
    Tornesello AL; Aurilio M; Accardo A; Tarallo L; Barbieri A; Arra C; Tesauro D; Morelli G; Aloj L
    J Pept Sci; 2011 May; 17(5):405-12. PubMed ID: 21351319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel expression of gastrin (cholecystokinin-B) receptors in azaserine-induced rat pancreatic carcinoma: receptor determination and characterization.
    Zhou W; Povoski SP; Longnecker DS; Bell RH
    Cancer Res; 1992 Dec; 52(24):6905-11. PubMed ID: 1458479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.
    Roosenburg S; Laverman P; Joosten L; Cooper MS; Kolenc-Peitl PK; Foster JM; Hudson C; Leyton J; Burnet J; Oyen WJ; Blower PJ; Mather SJ; Boerman OC; Sosabowski JK
    Mol Pharm; 2014 Nov; 11(11):3930-7. PubMed ID: 24992368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptides.
    Laverman P; Joosten L; Eek A; Roosenburg S; Peitl PK; Maina T; Mäcke H; Aloj L; von Guggenberg E; Sosabowski JK; de Jong M; Reubi JC; Oyen WJ; Boerman OC
    Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1410-6. PubMed ID: 21461732
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.